MAP1S and breast carcinoma: In agreement with this study, we observed that elevated MAP1S levels were accompanied by degradation of MyD88 and attenuation of MyD88-dependent transcription factor activation, suggesting that MAP1S provides negative feedback regulation in the TLR5 signaling pathway of breast cancer cells.